LCM
BDTX icon

Laurion Capital Management’s Black Diamond Therapeutics BDTX Stock Holding History

Laurion Capital Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-878,286
Closed -$4.45M – 566
2024
Q1 		$4.45M Buy
+878,286
New +$3.54M 0.04% 268
2020
Q3 		– Sell
-5,000
Closed -$211K – 845
2020
Q2 		$211K Buy
+5,000
New +$184K ﹤0.01% 779

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Laurion Capital Management's BDTX Position: Q2 2024 in Review

Laurion Capital Management sold out of Black Diamond Therapeutics (BDTX) in Q2 2024, closing a stake of 878,286 shares — an estimated $4.45M sold.

Laurion Capital Management first reported a position in BDTX in Q2 2020 and held it in 2 quarters. The position peaked at $4.45M in Q1 2024. 90 funds tracked by Wall St. Rank hold BDTX as of Q2 2024.

  • Laurion Capital Management reported no remaining Black Diamond Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Laurion Capital Management sold 878,286 Black Diamond Therapeutics shares in Q2 2024, an estimated $4.45M.
  • Laurion Capital Management first reported a position in Black Diamond Therapeutics in Q2 2020 and held it in 2 quarters.
  • Laurion Capital Management's Black Diamond Therapeutics position peaked at $4.45M in Q1 2024.
  • 90 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2024.

Based on Laurion Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.